127 related articles for article (PubMed ID: 28502278)
1. A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR DEVICES: THE FIRST FIVE YEARS.
Campbell B; Dobson L; Higgins J; Dillon B; Marlow M; Pomfrett C
Int J Technol Assess Health Care; 2017 Jan; 33(1):19-24. PubMed ID: 28502278
[TBL] [Abstract][Full Text] [Related]
2. ASSESSING THE VALUE OF INNOVATIVE MEDICAL DEVICES AND DIAGNOSTICS: THE IMPORTANCE OF CLEAR AND RELEVANT CLAIMS OF BENEFIT.
Campbell B; Campbell M; Dobson L; Higgins J; Dillon B; Marlow M; Pomfrett CJD
Int J Technol Assess Health Care; 2018 Jan; 34(4):419-424. PubMed ID: 30025548
[TBL] [Abstract][Full Text] [Related]
3. Review of the role of NICE in promoting the adoption of innovative cardiac technologies.
Groves PH; Pomfrett C; Marlow M
Heart; 2018 Nov; 104(22):1817-1822. PubMed ID: 29773657
[TBL] [Abstract][Full Text] [Related]
4. Identifying and selecting new procedures for health technology assessment: a decade of nice experience in the United Kingdom.
Campbell B; Morris R; Mandava L; Murthy L; Gallo H; Ong KJ; Latif A; Patrick H
Int J Technol Assess Health Care; 2014 Oct; 30(4):454-60. PubMed ID: 25412656
[TBL] [Abstract][Full Text] [Related]
5. Cross-national comparison of technology assessment processes.
García-Altés A; Ondategui-Parra S; Neumann PJ
Int J Technol Assess Health Care; 2004; 20(3):300-10. PubMed ID: 15446760
[TBL] [Abstract][Full Text] [Related]
6. Does the National Institute for Health and Clinical Excellence only appraise new pharmaceuticals?
Linden L; Vondeling H; Packer C; Cook A
Int J Technol Assess Health Care; 2007; 23(3):349-53. PubMed ID: 17579938
[TBL] [Abstract][Full Text] [Related]
7. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
Cowles E; Marsden G; Cole A; Devlin N
Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance.
Crispi F; Naci H; Barkauskaite E; Osipenko L; Mossialos E
Appl Health Econ Health Policy; 2019 Apr; 17(2):189-211. PubMed ID: 30367349
[TBL] [Abstract][Full Text] [Related]
9. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).
Buxton M
Value Health; 2001; 4(3):212-6. PubMed ID: 11705183
[TBL] [Abstract][Full Text] [Related]
10. Translational health economics: The key to accountable adoption of in vitro diagnostic technologies.
Price CP; Wolstenholme J; McGinley P; St John A
Health Serv Manage Res; 2018 Feb; 31(1):43-50. PubMed ID: 29084478
[TBL] [Abstract][Full Text] [Related]
11. PROMISE AND PLAUSIBILITY: HEALTH TECHNOLOGY ADOPTION DECISIONS WITH LIMITED EVIDENCE.
Campbell B; Knox P
Int J Technol Assess Health Care; 2016 Jan; 32(3):122-5. PubMed ID: 27530151
[TBL] [Abstract][Full Text] [Related]
12. The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.
Kaltenthaler E; Carroll C; Hill-McManus D; Scope A; Holmes M; Rice S; Rose M; Tappenden P; Woolacott N
Health Technol Assess; 2016 Apr; 20(26):1-48. PubMed ID: 27049841
[TBL] [Abstract][Full Text] [Related]
13. Closing the loop between horizon scanning and health technology assessment - an overview of topics submitted for appraisal in England.
Khan SK; Gonzalez-Moral SG; Lanyi K; Ogunbayo D; Craig D
Int J Technol Assess Health Care; 2023 Sep; 39(1):e64. PubMed ID: 37690810
[TBL] [Abstract][Full Text] [Related]
14. National Institute for Health and Clinical Excellence: the Medical Technologies Evaluation Programme.
J Med Eng Technol; 2011 Jul; 35(5):283-4. PubMed ID: 21635177
[TBL] [Abstract][Full Text] [Related]
15. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
Towse A; Pritchard C
Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
17. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
[TBL] [Abstract][Full Text] [Related]
18. Moving low value care lists into action: prioritizing candidate health technologies for reassessment using administrative data.
Soril LJJ; Seixas BV; Mitton C; Bryan S; Clement FM
BMC Health Serv Res; 2018 Aug; 18(1):640. PubMed ID: 30111308
[TBL] [Abstract][Full Text] [Related]
19. Quality, innovation, and value for money: NICE and the British National Health Service.
Pearson SD; Rawlins MD
JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
[TBL] [Abstract][Full Text] [Related]
20. Using health outcomes data to inform decision-making: government agency perspective.
Taylor R
Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
